Key facts
- This page summarizes Raj Mehra's Form 4 filing for SEELOS THERAPEUTICS, INC..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 01 Dec 2023, 16:16.
Raj Mehra - 01 Dec 2023 Form 4 Insider Report for SEELOS THERAPEUTICS, INC.
- Reporting relationship
- President, Chief Executive Officer and Chairman of the Board of Directors, Director
- Issuer ticker
- N/A
- Reported as of
- 01 Dec 2023
- Net transaction value
- +$99,999
- SEC form
- 4
- Accepted by SEC
- 01 Dec 2023, 16:16:02 UTC
- Prior SEC filing
- 31 Mar 2023
- Next SEC filing
- 17 Jan 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Raj Mehra
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Raj Mehra filed Form 4 for SEELOS THERAPEUTICS, INC. on 01 Dec 2023.
Change
- Previous filing in this sequence was filed on 31 Mar 2023.
- Current net transaction value: +$99,999.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SEEL
transaction
Common Stock
Purchase
- Transaction value
- $99,999
- Shares
- +75,757
- Change %
- +69%
- Price
- $1.32*
- Shares after
- 185,142
- Date
- 01 Dec 2023
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SEEL
transaction
Derivative
Common Stock Warrant (right to buy)
Purchase
- Transaction value
- Shares
- +75,757
- Change %
- Price
- Shares after
- 75,757
- Date
- 01 Dec 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 75,757
- Exercise price
- $1.32
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each share of common stock was purchased together with an accompanying warrant to purchase one share of common stock in an underwritten public offering at a combined offering price of $1.32 per share of common stock and accompanying warrant.
Footnote F2
Effective on November 28, 2023, the Issuer conducted a reverse stock split at a ratio of 1-for-30 (the "Reverse Split"). The number of shares reported herein reflects the number of shares after the Reverse Split.
SEC remarks
President, Chief Executive Officer and Chairman of the Board of Directors